Seeing Is Believing
Currently out of the existing stock ratings of Andreas Argyrides, 96 are a BUY (82.05%), 16 are a HOLD (13.68%), 5 are a SELL (4.27%).
Analyst Andreas Argyrides, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 34.22% that have a potential upside of 50.5% achieved within 125 days. Previously, Andreas Argyrides worked at WEDBUSH.
Andreas Argyrides’s has documented 231 price targets and ratings displayed on 30 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on DYN, Dyne Therapeutics at 09-Oct-2025.
Analyst best performing recommendations are on MNPR (MONOPAR THERAPEUTICS).
The best stock recommendation documented was for MNPR (MONOPAR THERAPEUTICS) at 9/3/2025. The price target of $77 was fulfilled within 22 days with a profit of $40.79 (112.65%) receiving and performance score of 51.2.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$34
$22.27 (189.86%)
$34
1 months 12 days ago
(07-Sep-2025)
0/11 (0%)
$24.52 (258.65%)
Buy
1 months 12 days ago
(07-Sep-2025)
0/6 (0%)
$28.77 (123.85%)
Hold
$12
$0.27 (2.30%)
$14
6 months 3 days ago
(16-Apr-2025)
1/3 (33.33%)
$6.06 (102.02%)
174
Buy
$25
$13.27 (113.13%)
$30
6 months 17 days ago
(02-Apr-2025)
4/14 (28.57%)
$18.33 (274.81%)
50
Buy
$24
$12.27 (104.60%)
$22
7 months 6 days ago
(13-Mar-2025)
0/2 (0%)
$17.28 (257.14%)
Which stock is Andreas Argyrides is most bullish on?
Which stock is Andreas Argyrides is most reserved on?
What Year was the first public recommendation made by Andreas Argyrides?